Search results for "Viral Load"

showing 10 items of 232 documents

A European multicentre evaluation of detection and typing methods for human enteroviruses and parechoviruses using RNA transcripts

2020

Polymerase chain reaction (PCR) detection has become the gold standard for diagnosis and typing of enterovirus (EV) and human parechovirus (HPeV) infections. Its effectiveness depends critically on using the appropriate sample types and high assay sensitivity as viral loads in cerebrospinal fluid samples from meningitis and sepsis clinical presentation can be extremely low. This study evaluated the sensitivity and specificity of currently used commercial and in‐house diagnostic and typing assays. Accurately quantified RNA transcript controls were distributed to 27 diagnostic and 12 reference laboratories in 17 European countries for blinded testing. Transcripts represented the four human EV…

EchovirusGene DosageDIVERSITYCHILDRENmedicine.disease_causelaw.invention0302 clinical medicinelawEPIDEMIOLOGY030212 general & internal medicineResearch ArticlesComputingMilieux_MISCELLANEOUSPolymerase chain reaction*enterovirus*enterovirus A7111832 Microbiology and virologyenterovirusRNA transcripts[SDE.IE]Environmental Sciences/Environmental EngineeringHuman parechovirusCLINICAL-SAMPLESASSOCIATIONMeningitis Viral3. Good healthEuropeenterovirus A71PCRInfectious Diseases*RNA transcriptsINFECTIONS[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology*PCRRNA Viral030211 gastroenterology & hepatologyLife Sciences & BiomedicineViral loadResearch Article[SDE.MCG]Environmental Sciences/Global ChangesBiologyReal-Time Polymerase Chain ReactionSensitivity and SpecificityPANEL03 medical and health sciencesCEREBROSPINAL-FLUIDVirologyEnterovirus InfectionsmedicineHumansRHINOVIRUSTypingparechovirusScience & TechnologyPicornaviridae InfectionsReproducibility of ResultsGold standard (test)biology.organism_classification[SDE.ES]Environmental Sciences/Environmental and SocietyVirology*parechovirusMolecular TypingParechovirusEnterovirusReagent Kits Diagnostic[SDE.BE]Environmental Sciences/Biodiversity and EcologyJournal of Medical Virology
researchProduct

HCV genotype 5: an orphan virus

2013

HCV genotype 5 (HCV-5) is the least known HCV genotype. It is found mainly in South Africa and in restricted areas of Belgium, Spain, France, Syria and Greece. Sporadic cases are reported worldwide. The main modes of transmission are blood transfusion and iatrogenic causes. Little is known about its origin, but various studies have elucidated its spread worldwide. In endemic areas, patients infected with HCV-5 are on average older and have a higher viral load and more advanced fibrosis than those infected with non-HCV-5 genotypes. The current standard of care for HCV-5 chronic infection is 48 weeks of dual therapy with pegylated interferon plus ribavirin. ‘Favourable’ Il28B polymorphisms a…

Blood transfusionGenotypemedicine.medical_treatmentHepacivirusAntiviral Agentschemistry.chemical_compoundPegylated interferonGenotypemedicinePrevalenceHumansPharmacology (medical)PharmacologyTransmission (medicine)business.industryRibavirinvirus diseasesHepatitis Cmedicine.diseaseHepatitis Cdigestive system diseasesChronic infectionInfectious DiseasesTreatment OutcomechemistryImmunologyHost-Pathogen InteractionsbusinessViral loadmedicine.drug
researchProduct

Antiretroviral therapy abrogates association between arginase activity and HIV disease severity

2010

AbstractArginase-induced L-arginine deprivation is emerging as a key mechanism for the downregulation of immune responses. We hypothesised that arginase activity increases with disease severity in HIV-seropositive patients. Our results show that peripheral blood mononuclear cells (PBMCs) from 23 HIV-seropositive patients with low CD4+ T cell counts (≤350 cells/μl) expressed significantly more arginase compared with 21 patients with high CD4+ T cell counts. Furthermore, we found a significant association between the two principal prognostic markers used to monitor HIV disease (CD4+ T cell count and plasma viral load) and PBMC arginase activity in antiretroviral therapy naïve patients but not…

MaleAnti-HIV AgentsT cellT cellsCD4 cell countL-arginineHIV InfectionsArgininePeripheral blood mononuclear cellSeverity of Illness Index03 medical and health sciences0302 clinical medicineImmune systemImmunopathologymedicineHumansImmune response030304 developmental biology0303 health sciencesbiologyArginasebusiness.industryPublic Health Environmental and Occupational HealthHIVGeneral MedicineViral Loadbiology.organism_classification3. Good healthCD4 Lymphocyte CountArginaseInfectious Diseasesmedicine.anatomical_structureSociety Meeting PaperLentivirusImmunologyHIV-1Leukocytes MononuclearParasitologyFemaleViral diseasebusinessViral load030217 neurology & neurosurgeryTransactions of the Royal Society of Tropical Medicine and Hygiene
researchProduct

MMP-7 promoter polymorphisms do not influence CD4+ recovery and changes in plasma viral load during antiretroviral therapy for HIV-1 infection.

2005

Summary Matrix metalloproteinase-7 (MMP-7) generates soluble Fas Ligand (FasL), which is involved in the apoptotic loss of CD4+ T cells during HIV infection. We evaluated whether two polymorphisms in MMP-7 promoter could influence CD4+ recover in response to antiretroviral therapy, and found that these polymorphisms are ineffective.

AdultCD4-Positive T-LymphocytesMaleImmunologyHuman immunodeficiency virus (HIV)HIV InfectionsMatrix metalloproteinasemedicine.disease_causeMMP-7; Fas ligand; CD4T cells; HIV infectionFas ligandPlasma viral loadGeneticsHumansMedicineMolecular BiologyGenetics (clinical)Polymorphism Geneticbusiness.industryMetalloendopeptidasesGeneral MedicineMiddle AgedViral LoadAntiretroviral therapySoluble fas ligandCD4 Lymphocyte CountAnti-Retroviral AgentsApoptosisMatrix Metalloproteinase 7ImmunologyHIV-1business
researchProduct

Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease.

2008

Background & Aims: The natural course of chronic hepatitis C (CHC) in children is not well understood. The aim of this study was to assess the long-term course of CHC in a large sample of otherwise healthy children. Methods: From 1990 to 2005, 504 consecutive antihepatitis C virus (HCV)-positive children were enrolled at 12 centers of a national observatory and were followed up retrospectively/prospectively. Results: Putative exposure was perinatal in 283 (56.2%) cases, parenteral in 158 (31.3%), and unknown in 63 (12.5%). At baseline, 477 (94.6%) cases were HCV RNA seropositive, 118 (24.7%) of which were treated with standard interferon α. Ten years after putative exposure, the outcome in …

Liver CirrhosisMaleTime FactorsHepacivirusHepacivirusChronic hepatitis CGastroenterologyLiver diseaseViralProspective StudiesChronicProspective cohort studyChildChildrenchronic epatitis C; long term course; childrenbiologyHazard ratioGastroenterologyHepatitis CViral LoadHepatitis CTreatment OutcomeItalyChild PreschoolHCVDisease ProgressionRNA ViralFemaleViral loadmedicine.medical_specialtyAdolescentGenotypeAlpha interferonSocio-culturaleViremiaAntiviral AgentsRisk AssessmentHEPATITISInternal medicinemedicineHumansViremiaAdolescent; Antiviral Agents; Child; Child Preschool; Disease Progression; Female; Genotype; Hepatitis C Chronic; Humans; Infant; Interferon-alpha; Italy; Liver Cirrhosis; Male; Proportional Hazards Models; Prospective Studies; RNA Viral; Retrospective Studies; Risk Assessment; Time Factors; Treatment Outcome; Viral Load; Viremia; Hepacivirus; GastroenterologyPreschoolProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industryLong-term courseInfantInterferon-alphaHepatitis C Chronicbiology.organism_classificationmedicine.diseaseImmunologyRNAbusinessGastroenterology
researchProduct

Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy

2018

Background In 2017, oral direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection became available free of charge for all HCV-RNA-positive patients, irrespective of their fibrosis stage. Aim The aim of this study was to evaluate the characteristics of HCV-related chronic liver disease (CLD) in Italy just before the introduction of DAA therapy. Patients and methods Patients with CLD were enrolled in two national surveys conducted in 2001 and in 2014. The two surveys prospectively enrolled patients aged older than 18 years referring to Italian liver units throughout the country using a similar clinical approach and analytical methods. Results Out of the 12 564 patie…

MaleCirrhosisTime FactorsAdministration OralHepacivirusmedicine.disease_causeChronic liver diseaseSeverity of Illness Index0302 clinical medicineRisk FactorsOdds RatioPrevalenceMedicine030212 general & internal medicineProspective StudiesMultivariate AnalysiGastroenterologyHealth SurveyMiddle AgedViral LoadItalyRNA Viral030211 gastroenterology & hepatologyFemaleHumanAdultmedicine.medical_specialtyLogistic ModelTime FactorGenotypeHepatitis C virusAntiviral AgentsVirus03 medical and health sciencesAge DistributionInternal medicinechronic hepatitis CHumansSex DistributionProtective FactorAgedAntiviral AgentCross-Sectional StudieHepatitis B virusHepaciviruChi-Square DistributionHepatologybusiness.industryRisk Factorchronic liver diseaseBiomarkerOdds ratioHepatitis C AntibodiesHepatitis C ChronicProtective Factorsmedicine.diseaseHealth SurveysConfidence intervaldirect-acting antiviral therapyProspective Studiehepatitis infectionCross-Sectional StudiesLogistic ModelsMultivariate AnalysisEtiologyHepatitis C AntibodiebusinessBiomarkers
researchProduct

Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.

2014

In hepatitis B e antigen (HBeAg) positive-HIV co-infected patients treated with combined antiretroviral therapy (cART), including tenofovir disoproxil fumarate (TDF), the rate of HBe seroconversion remains low. Whether adding pegylated interferon alfa (PegIFN) could increase the likelihood of HBeAg loss and HBe seroconversion has not been assessed.A 48-week PegIFN therapy was added to HBeAg positive-HIV co-infected patients on TDF and emtricitabine, or lamivudine for at least 6 months. The primary endpoint was HBV sustained response: HBe seroconversion with undetectable HBV DNA levels 24 weeks after completing PegIFN therapy (W72).Fifty-one patients (49 men, median age 46 years, range: 32-6…

AdultMalemedicine.medical_specialtyHBsAgOrganophosphonatesHIV Infectionsmedicine.disease_causeEmtricitabineGastroenterologyAntiviral AgentsDeoxycytidinePolyethylene GlycolsHepatitis B ChronicPegylated interferonInternal medicineAntiretroviral Therapy Highly ActivemedicineEmtricitabineHumansHepatitis B e AntigensSeroconversionTenofovirHepatitis B virusDrug CarriersHepatologybusiness.industryCoinfectionAdeninevirus diseasesLamivudineHIVInterferon-alphaMiddle AgedViral Loaddigestive system diseasesRecombinant ProteinsCD4 Lymphocyte CountTreatment OutcomeHBeAgLamivudineImmunologyFemalebusinessViral loadmedicine.drugJournal of hepatology
researchProduct

Stable changes in CD4+ T lymphocyte miRNA expression after exposure to HIV-1

2012

Abstract MicroRNAs (miRNAs) inhibit HIV-1 expression by either modulating host innate immunity or by directly interfering with viral mRNAs. We evaluated the expression of 377 miRNAs in CD4+ T cells from HIV-1 élite long-term nonprogressors (éLTNPs), naive patients, and multiply exposed uninfected (MEU) patients, and we observed that the éLTNP patients clustered with naive patients, whereas all MEU subjects grouped together. The discriminatory power of miRNAs showed that 21 miRNAs significantly differentiated éLTNP from MEU patients and 23 miRNAs distinguished naive from MEU patients, whereas only 1 miRNA (miR-155) discriminated éLTNP from naive patients. We proposed that miRNA expression ma…

AdultCD4-Positive T-LymphocytesMaleTime FactorsImmunologyHIV InfectionsHIV Envelope Protein gp120BiologyBiochemistryImmune systemmultiply exposed uninfectedmicroRNAHumansDroshamiRNAInnate immune systemélite long-term nonprogressorsGene Expression ProfilingCell BiologyHematologyT lymphocyteMiddle AgedViral LoadMicroarray AnalysisHIV-1; miRNA; CD4+ T cells; élite long-term nonprogressors; multiply exposed uninfected.CD4+ T cellsIn vitroMicroRNAsGene Expression RegulationCase-Control StudiesImmunologyHIV-1biology.proteinFemaleEx vivoDicerBlood
researchProduct

IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus …

2012

Background. Polymorphisms in the interleukin-28B are important determinants in the spontaneous and drug-induced control of hepatitis C virus infection. Design and Methods. We assessed the association of rs8099917 and rs12979860 polymorphisms with spontaneous viral clearance, severity of liver fibrosis, and response to interferon-monotherapy in 245 Thalassemia Major patients with Hepatitis C Virus infection. Results. Ninety-eight patients (40%) had a spontaneous viral clearance, while 147 patients (60%) developed a chronic infection. Spontaneous viral clearance was more frequent among patients with the T/T genotype of rs8099917 polymorphism (OR 2.130; p=0.008) or C/C genotype of rs12979860 p…

AdultLiver CirrhosisMalethlassemia hepatitis CInterferon InducersAdolescentHepacivirusHepatitis C virusAlpha interferonHepacivirusAdolescent; Adult; Antibodies Viral; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Chronic; Humans; Interferon Inducers; Interferon-alpha; Interleukins; Liver Cirrhosis; Male; Polymorphism Single Nucleotide; Prognosis; Viral Load; Young Adult; beta-Thalassemiamedicine.disease_causeAntibodies ViralAntiviral AgentsPolymorphism Single NucleotideCohort StudiesYoung AdultGenotypemedicineHumansInterferon inducerbiologymedicine.diagnostic_testInterleukinsbeta-ThalassemiaInterferon-alphaHematologyHepatitis CHepatitis C ChronicViral Loadbiology.organism_classificationmedicine.diseasePrognosisLiver biopsyImmunologyFemaleInterferonsOriginal Articles and Brief ReportsViral loadFollow-Up Studies
researchProduct

Assessment of prevalence and load of torquetenovirus viraemia in a large cohort of healthy blood donors.

2020

OBJECTIVES: Torquetenovirus (TTV) is an emerging marker of functional immune competence with the potential to predict transplant-related adverse events. A large-scale epidemiological study was performed to understand how basal values vary in healthy individuals according to age and gender.; METHODS: We tested plasma from 1017 healthy blood donors aged 18-69years. The presence and load of TTV were determined by a real-time PCR assay. A sub-cohort of 384 donors was tested for anti-cytomegalovirus IgG antibodies, and 100 participants were also tested for TTV viraemia on a paired whole blood sample.; RESULTS: The overall prevalence of TTV was 65% (657/1017) with a mean (±SD) growth of 5±4% ever…

0301 basic medicineMicrobiology (medical)AdultMalemedicine.medical_specialtyAgingAdolescentprevalence030106 microbiologyPcr assayPhysiologyTTVViremiaBlood DonorsanelloviridaeReal-Time Polymerase Chain Reaction03 medical and health sciencesPlasmaYoung Adult0302 clinical medicineEpidemiologyMedicineHumansBlood Transfusion030212 general & internal medicineViremiaTTV; anelloviridae; blood donors; healthy controls; prevalence; torquetenovirus; viremiaAdverse effectWhole bloodAgedTorque teno virusbiologybusiness.industryGeneral MedicineMiddle AgedViral Loadmedicine.diseaseDNA Virus InfectionsHealthy VolunteersLarge cohorttorquetenovirusInfectious DiseasesHealthy individualsDNA Viralbiology.proteinhealthy controlsFemaleAntibodybusinessClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
researchProduct